Sigyn Therapeutics Announces Corporate Update Webinar

May 18, 2021 at 08:30 AM EDT

The Event Occurs Friday, May 21^stat 11am Eastern / 8am Pacific Time

San Diego, CA - (NewMediaWire) - May 18, 2021 - Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions, announced today that its Chairman and CEO, Jim Joyce will give a “live” corporate update webinar this Friday, May 21st at 11am eastern time.

Mr. Joyce will review a series of recent milestones that support the advancement of Sigyn Therapy™, a novel blood purification technology designed to treat sepsis and other life-threatening conditions precipitated by cytokine storm syndrome. Mr. Joyce will also discuss the expansion of the Sigyn team, the Company’s improved balance sheet and forthcoming studies whose results will be included in an Investigational Device Exemption (IDE) that the Company plans to file with the United States Food and Drug Administration (FDA).

To register for the event, click on the following link: https://forcewealth.com/portfolio-items/sigyn-05-21/?portfolioCats=28

About Sigyn Therapeutics

Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

To learn more, visit www.SigynTherapeutics.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jj@sigyntherapeutics.com

Symbol	Price	Change (%)
AMZN	217.38	-4.65 (-2.09%)
AAPL	260.59	-2.18 (-0.83%)
AMD	230.04	-7.99 (-3.36%)
BAC	50.80	-0.72 (-1.39%)
GOOG	253.33	+1.99 (0.79%)
META	732.06	-1.21 (-0.17%)
MSFT	522.53	+4.88 (0.94%)
NVDA	179.57	-1.59 (-0.88%)
ORCL	271.15	-4.00 (-1.45%)
TSLA	434.76	-7.84 (-1.77%)

Symbol

Price

Change (%)

AMZN

217.38

-4.65 (-2.09%)

AAPL

260.59

-2.18 (-0.83%)

AMD

230.04

-7.99 (-3.36%)

BAC

50.80

-0.72 (-1.39%)

GOOG

253.33

+1.99 (0.79%)

About Us

About Cabling Installation & Maintenance

Contact Cabling Installation & Maintenance

Editorial

Advertising and Sponsorship Sales

Subscriptions and Memberships

Feedback/Problems

Sigyn Therapeutics Announces Corporate Update Webinar

More News

Recent Quotes